DTC ads to be part of “full court press” in marketing of Exubera

Share this article:
Pfizer has confirmed plans to mount a branded DTC advertising campaign behind Exubera as it attempts to turn around “disappointing” sales of the inhaled insulin product. “While we remain convinced that Exubera offers substantial benefit for diabetic patients worldwide, we are disappointed with the product’s performance to date,” Pfizer CEO Jeff Kindler said during a conference call with analysts. As a result, Pfizer will initiate a “full court press” behind the product, said president, worldwide pharmaceutical operations, Ian Read. Earlier this month, Pfizer’s cardiovascular field forces began supporting Exubera. Launch of the DTC ad campaign can be expected sometime during the second half of 2007, “when we feel it’s the right time,” Read said. “Right now we are really focused on watching the product grow.” In February, Read told Bloomberg News that Pfizer planned a DTC ad campaign targeting newly diagnosed diabetics who may not want to inject themselves daily. “The heart of the issue in diabetes therapy is the delay in getting patients to begin taking insulin, a delay that often lasts more than eight years.” Read said. However, Exubera has gone largely spurned by diabetes specialists so far. Although Pfizer has declined to make public its sales figures for Exubera, most estimates find the product generated only about $5 million in sales for 2006, or one-tenth as much as much as some analysts initially forecasted.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...